In a phase 3 randomized controlled trial, escitalopram was not associated with significant improvement in agitation symptoms in patients with Alzheimer dementia and was linked to QT interval prolongation,...
Agitation in frontotemporal lobar degeneration is linked to distinct neuropsychiatric symptom profiles between men and women, with men showing a broader spectrum of associated symptoms, particularly in...
New clinical guidance outlines the use of blood-based biomarker tests for Alzheimer’s diagnosis in patients with cognitive impairment, aiming to support more consistent and evidence-based application in...
Using positron emission tomography and explainable artificial intelligence, researchers have identified a brain network that predicts the onset of psychosis in Alzheimer disease and correlates with...
In a recent multicenter study, brexpiprazole showed significant efficacy in reducing agitation symptoms in Japanese patients with Alzheimer dementia, marking the first confirmation of its effectiveness in...
Researchers analyzed patient data from the Alzheimer’s Disease in Down Syndrome study to determine the sex differences in Alzheimer-related neuropsychiatric symptomology among adults with Down syndrome.
...
Researchers set out to determine whether attention-deficit/hyperactivity disorder predisposes individuals to the development of neuropsychiatric symptoms. The researchers presented their findings at the...
A study found several neuropsychiatric symptoms in patients with Alzheimer disease, such as aggression, anxiety, and disinhibition, were significantly associated with worsening functional abilities.
A study investigated the neural mechanisms behind aggressive behaviors in patients with Alzheimer disease and amnestic mild cognitive impairment, revealing distinct associations between brain activity and...
A study on mild cognitive impairment found that depression and agitation are linked to regional brain atrophy and faster cognitive decline, suggesting these symptoms may indicate a higher risk for...
